Patient-derived organoid models help define personalized management of gastrointestinal cancer

M. R. Aberle, Richard Burkhart, H. Tiriac, S. W.M. Olde Damink, C. H.C. Dejong, D. A. Tuveson, R. M. van Dam

Research output: Contribution to journalReview article

Abstract

Background: The prognosis of patients with different gastrointestinal cancers varies widely. Despite advances in treatment strategies, such as extensive resections and the addition of new drugs to chemotherapy regimens, conventional treatment strategies have failed to improve survival for many tumours. Although promising, the clinical application of molecularly guided personalized treatment has proven to be challenging. This narrative review focuses on the personalization of cancer therapy using patient-derived three-dimensional ‘organoid’ models. Methods: A PubMed search was conducted to identify relevant articles. An overview of the literature and published protocols is presented, and the implications of these models for patients with cancer, surgeons and oncologists are explained. Results: Organoid culture methods have been established for healthy and diseased tissues from oesophagus, stomach, intestine, pancreas, bile duct and liver. Because organoids can be generated with high efficiency and speed from fine-needle aspirations, biopsies or resection specimens, they can serve as a personal cancer model. Personalized treatment could become a more standard practice by using these cell cultures for extensive molecular diagnosis and drug screening. Drug sensitivity assays can give a clinically actionable sensitivity profile of a patient's tumour. However, the predictive capability of organoid drug screening has not been evaluated in prospective clinical trials. Conclusion: High-throughput drug screening on organoids, combined with next-generation sequencing, proteomic analysis and other state-of-the-art molecular diagnostic methods, can shape cancer treatment to become more effective with fewer side-effects.

Original languageEnglish (US)
Pages (from-to)e48-e60
JournalBritish Journal of Surgery
Volume105
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Organoids
Gastrointestinal Neoplasms
Preclinical Drug Evaluations
Neoplasms
Therapeutics
Molecular Pathology
Fine Needle Biopsy
Bile Ducts
PubMed
Pharmaceutical Preparations
Proteomics
Esophagus
Intestines
Pancreas
Stomach
Cell Culture Techniques
Clinical Trials
Drug Therapy
Survival
Liver

ASJC Scopus subject areas

  • Surgery

Cite this

Aberle, M. R., Burkhart, R., Tiriac, H., Olde Damink, S. W. M., Dejong, C. H. C., Tuveson, D. A., & van Dam, R. M. (2018). Patient-derived organoid models help define personalized management of gastrointestinal cancer. British Journal of Surgery, 105(2), e48-e60. https://doi.org/10.1002/bjs.10726

Patient-derived organoid models help define personalized management of gastrointestinal cancer. / Aberle, M. R.; Burkhart, Richard; Tiriac, H.; Olde Damink, S. W.M.; Dejong, C. H.C.; Tuveson, D. A.; van Dam, R. M.

In: British Journal of Surgery, Vol. 105, No. 2, 01.01.2018, p. e48-e60.

Research output: Contribution to journalReview article

Aberle, MR, Burkhart, R, Tiriac, H, Olde Damink, SWM, Dejong, CHC, Tuveson, DA & van Dam, RM 2018, 'Patient-derived organoid models help define personalized management of gastrointestinal cancer', British Journal of Surgery, vol. 105, no. 2, pp. e48-e60. https://doi.org/10.1002/bjs.10726
Aberle, M. R. ; Burkhart, Richard ; Tiriac, H. ; Olde Damink, S. W.M. ; Dejong, C. H.C. ; Tuveson, D. A. ; van Dam, R. M. / Patient-derived organoid models help define personalized management of gastrointestinal cancer. In: British Journal of Surgery. 2018 ; Vol. 105, No. 2. pp. e48-e60.
@article{9b835b2eab3c4560873d5c333b0714d9,
title = "Patient-derived organoid models help define personalized management of gastrointestinal cancer",
abstract = "Background: The prognosis of patients with different gastrointestinal cancers varies widely. Despite advances in treatment strategies, such as extensive resections and the addition of new drugs to chemotherapy regimens, conventional treatment strategies have failed to improve survival for many tumours. Although promising, the clinical application of molecularly guided personalized treatment has proven to be challenging. This narrative review focuses on the personalization of cancer therapy using patient-derived three-dimensional ‘organoid’ models. Methods: A PubMed search was conducted to identify relevant articles. An overview of the literature and published protocols is presented, and the implications of these models for patients with cancer, surgeons and oncologists are explained. Results: Organoid culture methods have been established for healthy and diseased tissues from oesophagus, stomach, intestine, pancreas, bile duct and liver. Because organoids can be generated with high efficiency and speed from fine-needle aspirations, biopsies or resection specimens, they can serve as a personal cancer model. Personalized treatment could become a more standard practice by using these cell cultures for extensive molecular diagnosis and drug screening. Drug sensitivity assays can give a clinically actionable sensitivity profile of a patient's tumour. However, the predictive capability of organoid drug screening has not been evaluated in prospective clinical trials. Conclusion: High-throughput drug screening on organoids, combined with next-generation sequencing, proteomic analysis and other state-of-the-art molecular diagnostic methods, can shape cancer treatment to become more effective with fewer side-effects.",
author = "Aberle, {M. R.} and Richard Burkhart and H. Tiriac and {Olde Damink}, {S. W.M.} and Dejong, {C. H.C.} and Tuveson, {D. A.} and {van Dam}, {R. M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/bjs.10726",
language = "English (US)",
volume = "105",
pages = "e48--e60",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Patient-derived organoid models help define personalized management of gastrointestinal cancer

AU - Aberle, M. R.

AU - Burkhart, Richard

AU - Tiriac, H.

AU - Olde Damink, S. W.M.

AU - Dejong, C. H.C.

AU - Tuveson, D. A.

AU - van Dam, R. M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The prognosis of patients with different gastrointestinal cancers varies widely. Despite advances in treatment strategies, such as extensive resections and the addition of new drugs to chemotherapy regimens, conventional treatment strategies have failed to improve survival for many tumours. Although promising, the clinical application of molecularly guided personalized treatment has proven to be challenging. This narrative review focuses on the personalization of cancer therapy using patient-derived three-dimensional ‘organoid’ models. Methods: A PubMed search was conducted to identify relevant articles. An overview of the literature and published protocols is presented, and the implications of these models for patients with cancer, surgeons and oncologists are explained. Results: Organoid culture methods have been established for healthy and diseased tissues from oesophagus, stomach, intestine, pancreas, bile duct and liver. Because organoids can be generated with high efficiency and speed from fine-needle aspirations, biopsies or resection specimens, they can serve as a personal cancer model. Personalized treatment could become a more standard practice by using these cell cultures for extensive molecular diagnosis and drug screening. Drug sensitivity assays can give a clinically actionable sensitivity profile of a patient's tumour. However, the predictive capability of organoid drug screening has not been evaluated in prospective clinical trials. Conclusion: High-throughput drug screening on organoids, combined with next-generation sequencing, proteomic analysis and other state-of-the-art molecular diagnostic methods, can shape cancer treatment to become more effective with fewer side-effects.

AB - Background: The prognosis of patients with different gastrointestinal cancers varies widely. Despite advances in treatment strategies, such as extensive resections and the addition of new drugs to chemotherapy regimens, conventional treatment strategies have failed to improve survival for many tumours. Although promising, the clinical application of molecularly guided personalized treatment has proven to be challenging. This narrative review focuses on the personalization of cancer therapy using patient-derived three-dimensional ‘organoid’ models. Methods: A PubMed search was conducted to identify relevant articles. An overview of the literature and published protocols is presented, and the implications of these models for patients with cancer, surgeons and oncologists are explained. Results: Organoid culture methods have been established for healthy and diseased tissues from oesophagus, stomach, intestine, pancreas, bile duct and liver. Because organoids can be generated with high efficiency and speed from fine-needle aspirations, biopsies or resection specimens, they can serve as a personal cancer model. Personalized treatment could become a more standard practice by using these cell cultures for extensive molecular diagnosis and drug screening. Drug sensitivity assays can give a clinically actionable sensitivity profile of a patient's tumour. However, the predictive capability of organoid drug screening has not been evaluated in prospective clinical trials. Conclusion: High-throughput drug screening on organoids, combined with next-generation sequencing, proteomic analysis and other state-of-the-art molecular diagnostic methods, can shape cancer treatment to become more effective with fewer side-effects.

UR - http://www.scopus.com/inward/record.url?scp=85040725673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040725673&partnerID=8YFLogxK

U2 - 10.1002/bjs.10726

DO - 10.1002/bjs.10726

M3 - Review article

VL - 105

SP - e48-e60

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 2

ER -